TRAZOGASTRO

Indications

• Intravenous urography
• Angiography
• Computed tomography (CT) imaging
• Cholecystography
• Myelography

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing, as it is determined based on age, weight, and type of procedure.

Adults: Refer to specific product guidelines and protocols for adult dosing, as it varies based on the imaging procedure and patient condition.

Mechanism of action

Diatrizoic acid works by increasing the attenuation of X-rays. As a high atomic number iodine compound, it absorbs X-rays more effectively than surrounding tissues, thereby enhancing the contrast in imaging studies. The iodine atoms in diatrizoic interact with the X-ray photons, resulting in greater visibility of vascular structures and organs during imaging.

Pharmacodynamics

Diatrizoic exhibits its pharmacological effect primarily by altering the radiopacity of tissues in response to X-ray exposure. The contrast enhancement allows for better visualization of anatomical structures, aiding in the diagnosis of various conditions, including tumors, vascular anomalies, and gastrointestinal disorders. The pharmacodynamic profile is characterized by rapid onset of action, as the contrast medium is administered directly into the vascular system or body cavities.

Pharmacokinetics

Diatrizoic is administered intravenously or intrathecally, depending on the imaging procedure. Upon administration, it is rapidly distributed throughout the vascular system. The contrast medium is primarily excreted unchanged by the kidneys, with renal clearance being the main route of elimination from the body. The half-life of diatrizoic is short, generally ranging from 1 to 2 hours, depending on renal function. Factors such as hydration status and renal health can impact the pharmacokinetics of this agent.

Contra-indications

• Hypersensitivity to diatrizoic acid or any of its components
• Severe dehydration
• Hyperthyroidism
• Pheochromocytoma
• Severe renal impairment

Adverse effects

• Nausea
• Vomiting
• Headache
• Dizziness
• Allergic reactions
• Renal impairment
• Extravasation
• Thyroid dysfunction

Interactions

• May interact with anticoagulants, increasing the risk of bleeding
• Use with caution in patients receiving nephrotoxic agents
• Potential interactions with medications affecting thyroid function

Precautions

• Use with caution in patients with renal impairment
• Ensure adequate hydration prior to administration
• Monitor for signs of allergic reactions during and after administration
• Evaluate thyroid function in patients with thyroid disorders

Pregnancy

Diatrizoic should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a healthcare provider.

Breast-feeding

It is not known whether diatrizoic is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, protected from light. Do not freeze.

Formulations

• Injection solution
• Oral solution

Indications

• Used as a solubilizing agent in pharmaceutical preparations
• Used in radiographic contrast media formulations

Dosage

Children: Refer to specific formulations for paediatric dosing instructions as it varies depending on the application.

Adults: Refer to specific formulations for adult dosing instructions as it varies depending on the application.

Mechanism of action

Meglumine acts by enhancing the solubility and stability of drugs in solution, particularly in radiographic contrast agents. It is involved in purinergic signaling pathways, which are essential for various physiological processes, including neurotransmission and inflammation.

Pharmacodynamics

The pharmacodynamic profile of meglumine is largely influenced by its role as a solubilizing agent. It does not exhibit direct pharmacological effects on its own but rather facilitates the action of other active ingredients in formulations. Its impact on purinergic signaling may contribute to modulating physiological responses in the body.

Pharmacokinetics

Meglumine is rapidly absorbed when administered, with its pharmacokinetics closely tied to the properties of the drugs it accompanies. The distribution, metabolism, and excretion of meglumine are not well-defined as it typically functions as an excipient rather than an active therapeutic agent. Its elimination from the body is primarily via renal pathways.

Pregnancy

There is insufficient data on the use of meglumine in pregnancy, therefore it should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering meglumine to breastfeeding women, as its effects on infants are not well studied.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.